Versartis Inc. (Nasdaq: VSAR) reported disappointing results from a VELOCITY Phase 3 clinical trial of somavaratan to treat pediatric growth hormone deficiency. Shares of the biopharmaceutical collapsed $18.93 to close at $2.67.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |